MyLab is a Pune-based startup that provides diagnostic solutions. It had signed a collaboration with Ekincare, a corporate wellness and health benefits platform, to promote the NASOVAC-S4.

The respiratory illness influenza, usually referred to as flu, is characterized by fever, sore throat, cough, runny or stuffed nose, chills, headache, fatigue, and muscle aches and affects millions of individuals every year (1). This disease in a corporate setting will affect productivity and general well-being as it presents a serious health risk to the employees.

The CDC recommends that getting vaccinated against the flu is the first and most crucial step in preventing the illness each year. The risk of major flu complications, which can lead to hospitalization or even death, as well as flu-related diseases, has been demonstrated to be decreased by the flu vaccine. The CDC also suggests basic preventive measures to help hinder the spread of germs that cause respiratory (nose, throat, and lungs) illnesses like the flu, such as avoiding sick people, covering when you are coughing or sneezing, and frequently washing your hands (1).

The NASOVAC-S4 vaccination developed by the Serum Institute of India provides a cutting-edge and practical way to shield staff members from influenza and lessen the illness's possible effects on company operations. Also, since it is administered through the nasal route, it eliminates the traditional painful and invasive technique for vaccine administration. It contains two strains of the influenza Type A virus (A/H1N1 and A/H3N2) as well as two strains of the influenza Type B virus (Victoria and Yamagata lineages). It is a desirable choice for workplace flu vaccination campaigns due to its effectiveness and simplicity of administration.

Hasmukh Rawal, the co-founder and MD of MyLab remarked that MyLab was excited to work with Ekincare to promote NASOVAC-S4. He added that this collaboration emphasizes the commitment to improve public health and welfare through the provision of state-of-the-art healthcare solutions.

The CEO and co-founder of Ekincare, Kiran Kalakuntala, commented on this joint venture and stated that, since the health and welfare of employees is the most important aspect of any organization, this collaboration with MyLab would make the innovative vaccine available to all businesses across India. He further added that, by presenting NASOVAC-S4 to their corporate and healthcare insurance partners, they aimed to provide an efficient and readily available solution to protect employees from the flu.

(Input from various media sources)

Reference:

1) Key Facts About Influenza (Flu) | CDC [Internet] [cited November 29, 2023] Available from: https://www.cdc.gov/flu/about/keyfacts.htm

(Rehash/Bharkhavy K V)